Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma

Fig. 2

Differential expression of EGFR ligands in healthy and tumor tissue. A. Level of expression (measured by quantitative PCR) of the seven EGFR ligands in normal (n = 21, orange) and tumor (n = 23, purple) samples from renal cell carcinoma patients. Data are represented as 2^-delta Ct, in arbitrary units (a.u.). P values are indicated. B. Differential expression of TGFA in 19 cancer subtypes, both in normal and tumor tissue. RNA-Seq data were obtained from Firebrowse database and are represented as RPKM (reads per kilobase of exon model per million mapped reads). The expression of TGFA in kidney renal clear cell carcinoma is highlighted with a red dashed square, indicating the expression fold change between tumor and normal tissue. KIRC, kidney renal clear cell carcinoma; KIPAN, pan-kidney cohort; HNSC, head and neck squamous cell carcinoma; ESCA, esophageal carcinoma; LUSC, lung squamous cell carcinoma; THCA, thyroid carcinoma; LUAD, lung adenocarcinoma; KIRP, kidney renal papillary cell carcinoma; STES, stomach and esophageal carcinoma; BLCA, bladder urothelial carcinoma; STAD, stomach adenocarcinoma; COAD, colon adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; COADREAD, colorectal adenocarcinoma; READ, rectum adenocarcinoma; OV, ovarian serous cystadenocarcinoma; BRCA, breast invasive carcinoma; LIHC, liver hepatocellular carcinoma; LAML, acute myeloid leukemia. C. Differential expression of the seven EGFR ligands in kidney renal clear cell carcinoma and normal tissue. The plot shows the rank of this cancer subtype among the 19 analyzed ones in terms of ligand expression

Back to article page